
Cardiac Amyloidosis- Pipeline Insight, 2024
Description
Cardiac Amyloidosis- Pipeline Insight, 2024
DelveInsight’s, Cardiac Amyloidosis- Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cardiac Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cardiac Amyloidosis: Overview
Cardiac amyloidosis is one of the leading causes of restrictive cardiomyopathy. It typically presents with rapidly progressive diastolic dysfunction in a non-dilated ventricle. It is one of the under-diagnosed disease entities. The diagnosis of cardiac amyloidosis requires a high degree of suspicion, with cardiovascular imaging being pivotal in reaching the diagnosis.
The deposition of amyloid can lead to heart diseases in multiple ways. Direct interstitial infiltration leads to increased ventricular wall thickness, ventricular stiffness, and consequent ventricular diastolic dysfunction. In AL amyloidosis, amyloid can get deposited in arterioles leading to angina or, rarely, myocardial infarction. Amyloid infiltration in atria can lead to atrial interstitial changes, establishing a structural substrate for atrial fibrillation. Even in the absence of atrial fibrillation, atrial amyloidosis increases the risk of atrial thrombosis and thromboembolism. Light chains can also cause direct injury to the myocardial cells via reactive oxygen species.
""Cardiac Amyloidosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cardiac Amyloidosis pipeline landscape is provided which includes the disease overview and Cardiac Amyloidosis treatment guidelines. The assessment part of the report embraces, in depth Cardiac Amyloidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cardiac Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Cardiac Amyloidosis. The therapies under development are focused on novel approaches to treat/improve Cardiac Amyloidosis.
Acoramidis: Eidos Therapeutics
Eidos Therapeutics is developing a small molecule named Acoramidis (AG10), which was designed by researchers at Stanford University to potently stabilize TTR by mimicking the structure of the T119M TTR variant. T119M is known to protect carriers from developing ATTR due to the formation of unique bonds at the center of the molecule that stabilize the protein approximately 40-fold beyond the native structure. In pre-clinical studies, acoramidis (AG10) was shown to bind TTR tetramers at the same central locations at which the T119M variant forms stabilizing bonds. This unique binding mode is thought to underlie the potent stabilization of TTR by acoramidis (AG10).
NTLA-2001: Intellia Therapeutics
NTLA-2001 is the first CRISPR/Cas9-based therapy candidate to be administered systemically for precision editing of a gene in humans. It is designed to inactivate the TTR gene in liver cells to reduce the production of misfolded TTR protein, which accumulates in tissues throughout the body and causes the debilitating and often fatal complications of ATTR amyloidosis
Further product details are provided in the report……..
Cardiac Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the Cardiac Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cardiac Amyloidosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cardiac Amyloidosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cardiac Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cardiac Amyloidosis drugs.
Cardiac Amyloidosis Report Insights
- Cardiac Amyloidosis Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cardiac Amyloidosis drugs?
- How many Cardiac Amyloidosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cardiac Amyloidosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cardiac Amyloidosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cardiac Amyloidosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eidos Therapeutics
- Intellia Therapeutics
- Novo Nordisk
- Alnylam Pharmaceuticals
- Precision Biosciences
- Prothena
- Caelum Biosciences
- Zentalis Pharmaceuticals
- Attralus
- Acoramidis
- NTLA 2001
- PRX 004
- Vutrisiran
- ALN TTRsc04
- Birtamimab
- Anselamimab
- ZN d5
- Iodine (124I) evuzamitide
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Cardiac Amyloidosis: Overview
- What is Cardiac Amyloidosis?
- Types of Cardiac Amyloidosis
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Cardiac Amyloidosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Vutrisiran: Alnylam Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Iodine (124I) evuzamitide: Attralus
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- ALN TTRsc04: Alnylam Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cardiac AmyloidosisKey Companies
- Cardiac AmyloidosisKey Products
- Cardiac Amyloidosis- Unmet Needs
- Cardiac Amyloidosis- Market Drivers and Barriers
- Cardiac Amyloidosis- Future Perspectives and Conclusion
- Cardiac AmyloidosisAnalyst Views
- Cardiac AmyloidosisKey Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.